C-␥ . It also regulates distribution of phospholipids and PKC isoforms between MVs and PMs, enriching MVs in PKC-. Direct activation of MV MMP-3 requires ERp60 based on blocking antibodies and PKC based on inhibitor studies. However, treatment of MVs with 1,25(OH) 2 D 3 decreases MV PKC-activity, suggesting more complex feedback mechanisms, potentially involving MV lipid signaling. Our observations indicate that one role of MVs is to provide MMPs at sites distant from the cells. Chondrocytes secrete 1,25(OH) 2 D 3 , which acts directly on MV-membranes via ERp60, releasing MMPs. MMP-specific ECM components are hydrolyzed, resulting in release and activation of growth factors that can act back on the cells. 
Introduction
Growth plate chondrocytes produce a proteoglycanrich type II collagen extracellular matrix (ECM). As the cells in the growth plate mature and hypertrophy, there is a massive reorganization of the ECM to accommodate the changes in cell shape and to prepare the matrix for calcification and eventual vascular ingrowth. Concurrently, there is a shift in matrix-processing enzymes from neutral to acidic metalloproteinases . In addition, enzyme activities that modulate the size of proteoglycan aggregate, including chondroitinases and ADAMTS, are increased [Cawston and Wilson, 2006] .
In vivo studies have shown that activity of matrix processing enzymes in the growth plate is regulated by 1 ␣ ,25(OH) 2 D 3 Lin et al., 2002] . This phenomenon has been confirmed in studies using growth plate chondrocyte cultures [Schmitz et al., 1996b; Maeda et al., 2000] . There are a number of mechanisms by which this occurs. Many of the enzymes are produced as zymogens, and 1 ␣ ,25(OH) 2 D 3 increases zymogen activation [Schmitz et al., 1996b] . 1 ␣ ,25(OH) 2 D 3 has been shown to regulate the levels of mineral ions that are required for metalloproteinase activity [Brown et al., 1993] . In addition, 1 ␣ ,25(OH) 2 D 3 modulates transcription of their mRNA [Schmitz et al., 1996a, b] . Because regulation of matrix metalloproteinase (MMP) activity is critical, chondrocytes produce inhibitors like tissue inhibitor of metalloproteinases (TIMP-1 and TIMP-2) [Dean et al., 1992 ] and 1 ␣ ,25(OH) 2 D 3 modulates levels of these inhibitors as well .
We have shown that growth plate chondrocytes also take advantage of extracellular organelles called matrix vesicles (MVs) to package MMPs and store them in the ECM separate from the matrix proteins [Schmitz et al., 1994; Dean et al., 1996a, b; D'Angelo et al., 2001] . MVs produced by cells in the prehypertrophic and hypertrophic cell zones contain higher levels of acidic metalloproteinases and this is further increased in animals treated with 1 ␣ ,25(OH) 2 D 3 [Dean et al., 1996a, b] . In addition, 1 ␣ ,25(OH) 2 D 3 increases activity of neutral MMPs in MVs produced by these cells ( fig. 1 ). Cell culture studies have shown that incorporation of stromelysin-1 (MMP-3) and 72-kD gelatinase (MMP-2) into MVs is regulated by 1 ␣ ,25(OH) 2 D 3 [Schmitz et al., 1996b] . MMP-2 and MMP-3 are stored in MVs produced by growth zone chondrocytes together with TIMP-1 and TIMP-2, and are released from the MVs in an active form. 1 ␣ ,25(OH) 2 D 3 reduces MV TIMP levels , supporting the hypothesis that the MMPs are activated prior to their release in the matrix.
Autocrine Regulation of MV MMPs by 1 ␣ ,25(OH) 2 D 3
Traditionally, 1 ␣ ,25(OH) 2 D 3 acts via the vitamin D receptor to regulate gene transcription, so genetic modulation of MMP content during MV formation is not an unexpected finding. However, we have also shown that 1 ␣ ,25(OH) 2 D 3 can act directly on MVs, resulting in release of active MMPs [Dean et al., 1996b] nase C (PKC)-␣ -dependent signaling through a mechanism that is mediated by PLA 2 and requires the presence of PLA 2 -activating protein [Boyan et al., 2006] . Inhibition of PKC activity with chelerythrine blocks the effects of 1 ␣ ,25(OH) 2 D 3 on MMP-3 activity in isolated MVs [Maeda et al., 2000] , suggesting that a similar mechanism to that which occurs in chondrocytes may be involved, but it is unlikely that this is the case. During MV production, 1 ␣ ,25(OH) 2 D 3 regulates the differential distribution of PKC isoforms between the PM and the MV membrane, resulting in higher levels of PKC-␣ in the PM and higher levels of PKC-in the MVs [Sylvia et al., 1996] . However, when isolated PMs or MVs are treated directly with 1 ␣ ,25(OH) 2 D 3 , PKC-␣ activity is increased in the PM but PKC-activity is decreased in the MVs. This indicates that the direct action of the vitamin D metabolite is differentially distributed, allowing the responses to be specific to each membrane compartment.
In contrast to its effects on PKC isoforms, 1 ␣ ,25(OH) 2 D 3 stimulates PLA 2 activity in both membrane compartments [Schwartz et al., 2005] , suggesting an alternate hypothesis. In this hypothesis, activation of PLA 2 in the PM is rapidly downregulated, but in the MVs this does not occur and the resulting production of lysophospholipids causes a loss of membrane integrity and eventual release of MMPs into the ECM. That this is receptor mediated is evidenced by the fact that antibodies to ERp60 prevent the release of MV MMPs [Maeda et al., 2000] . Moreover, growth plate chondrocytes produce and secrete 1 ␣ ,25(OH) 2 D 3 in a regulated manner at levels as high as 10 -8 M , supporting the hypothesis that it acts in an autocrine manner.
Regulation of TGF-␤ Activation
Chondrocytes store TGF-␤ 1 in the growth plate ECM as large latent TGF-␤ 1 complexes, which consist of latent TGF-␤ 1-binding protein, latency-associated peptide and latent TGF-␤ 1 [Pedrozo et al., 1998 ]. Initial studies showed that 1 ␣ ,25(OH) 2 D 3 metabolites regulate expression of latent TGF-␤ 1-binding protein and latent TGF-␤ 1 and incorporation of latent TGF-␤ 1 in the ECM of chondrocytes [Pedrozo et al., 1999b] . TGF-␤ 1 regulates production of 1,25(OH) 2 D 3 by growth plate chondrocytes [Pedrozo et al., 1999a] , suggesting the possibility of a feedback loop modulating TGF-␤ 1 levels in the tissue.
The finding that 1 ␣ ,25(OH) 2 D 3 increased MMP activity suggested that 1 ␣ ,25(OH) 2 D 3 might also regulate availability of TGF-␤ 1 by controlling activation of the latent growth factor. Initial experiments on inhibition of TGF-␤ 1 activation by the MMP inhibitor 1,10-phenanthroline showed that MV extracts could activate latent TGF-␤ 1 and that MMPs were responsible for this ( fig. 3 ) . A second set of experiments demonstrated that extracts of MVs that had been incubated directly with 1 ␣ ,25-(OH) 2 D 3 were more effective than extracts of untreated MVs ( fig. 4 ) . Moreover, the effect of 1 ␣ ,25(OH) 2 D 3 was via activation of MMPs, based on the reduction in TGF-␤ 1 activation by 1,10-phenanthroline. 1 ␣ ,25(OH) 2 D 3 -treated MVs activated latent TGF-␤ 1 and to a lesser extent latent TGF-␤ 2 , suggesting that a similar mechanism was involved for both isoforms of this growth factor. Studies in other laboratories had shown that latent TGF-␤ could be activated by plasmin [Rosenthal et al., 2000] and we were able to show that plasmin could release active TGF-␤ 1 from ECM produced by growth plate chondrocytes [Pedrozo et al., 1999c] . However, MVs do not contain plasmin, indicating that another enzyme was involved. When MV extracts were treated with antibodies to MMP-3, activation of TGF-␤ 1 was blocked ], indicat- ing that it was responsible for 1 ␣ ,25(OH) 2 D 3 -dependent activation of latent TGF-␤ 1. Others have shown that MMP-2 specifically activates TGF-␤ 2 .
Taken together, these studies show that MVs contain enzymes that can result in the release of active TGF-␤ 1 from the ECM produced by growth plate chondrocytes. Moreover, they indicate that 1 ␣ ,25(OH) 2 D 3 produced by the cells and secreted into the ECM is involved. Additional studies have shown that the effect of 1 ␣ ,25(OH) 2 D 3 is mediated by 2 pathways, both of which are ERp60 dependent, based on the ability of antibodies to ERp60 to block the effect. One mechanism involves the activation of PLA2, resulting in the formation of lysophospholipids. Lysophospholipids can act directly on latent TGF-␤ 1, resulting in its activation [Gay et al., 2004] . They also function to destabilize the MV membrane, resulting in release of MMP-3 (an activator of TGF-␤ 1). The other mechanism is mediated by PKC, since inhibition of PKC by chelerythrine also prevents 1 ␣ ,25(OH) 2 D 3 -dependent activation of MV MMP-3 [Maeda et al., 2000 ].
Summary
The studies described above show that 1 ␣ ,25(OH) 2 D 3 regulates ECM turnover by activating both neutral and acidic matrix metalloproteinases. Part of this effect is via transcriptional regulation of MMP expression and part is via autocrine regulation of MMP release from extracellular MVs. MV MMP-3 specifically regulates activation of TGF-␤ 1 stored in the ECM, providing a feedback loop regulating matrix turnover. Active TGF-␤ 1 regulates 1 ␣ ,25(OH) 2 D 3 production and its secretion into the ECM. 1 ␣ ,25(OH) 2 D 3 acting as an autocrine factor acts directly on MVs via ERp60-dependent pathways, increasing local lysophospholipid content by stimulating PLA 2 activity and through control of PKC activity.
